Findings

What do systematic reviews say?

111 questions · 113 findings · 13 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 12 · 10.6%GRADE not reported 14 · 12.4%Very low 22 · 19.5%Low 31 · 27.4%Moderate 23 · 20.4%High 11 · 9.7%

Amantadine vs placebo

Risk for at least one adverse event per patient · patients with the treatment of cocaine dependence

Amantadine showed no clear difference in adverse events as N of participants with at least one adverse event compared with placebo (moderate certainty).

1 finding from 1 review

Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
RR 1.19 [0.69, 2.06]
4 studies · 128 participants
Moderate

Amantadine vs placebo

Abstinence · patients with the treatment of cocaine dependence

Amantadine showed no clear difference in abstinence (objective) N of subjects abstinent at the end of the study compared with placebo (low certainty).

2 findings from 1 review

Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
RR 1.13 [0.59, 2.13]
5 studies · 275 participants
Low
Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
RR 1.49 [1.03, 2.15]
3 studies · 76 participants
Moderate

Intervention not reported

Mortality · patients with hepatic encephalopathy.

The intervention showed no clear difference in mortality (low certainty).

1 finding from 1 review

Dopamine agents for hepatic encephalopathy 2014 · Cochrane Headline outcomes only
OR 1.11 [0.35, 3.54]
144 participants
Low

Intervention not reported

Hepatic encephalopathy · patients with hepatic encephalopathy.

The intervention showed no clear difference in hepatic encephalopathy (low certainty).

1 finding from 1 review

Dopamine agents for hepatic encephalopathy 2014 · Cochrane Headline outcomes only
OR 2.99 [0.09, 100.55]
80 participants
Low

Intervention not reported

IRLS cabergoline · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 127 participants
High

Intervention not reported

IRLS lisuride · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 378 participants
High

Intervention not reported

IRLS pergolide · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 97 participants
High

Intervention not reported

IRLS pramipexole · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 2256 participants
Moderate

Intervention not reported

IRLS ropinirole · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 2301 participants
Moderate

Intervention not reported

IRLS rotigotine · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 958 participants
High

Intervention not reported

IRLS sumanirole · patients with restless legs syndrome

1 finding from 1 review

Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 263 participants
High